Marhash *et al. J Pure Appl Microbiol,* **12(4)**, 2183-2192 Dec. 2018 http://dx.doi.org/10.22207/JPAM.12.4.57 Print ISSN: 0973-7510; Online ISSN: 2581-690X

RESEARCH ARTICLE



Detection and Phylogenetic Analysis of Human Papilloma Virus in Urine from a Sample of Iraqi Women with Vaginal Discharge

Ali D. Marhash¹, Qasim S. Al-Mayah², and Enas A.A. Al-Kazaaly³

¹Al-Furat Al-Awsat Technical University-Babylon Institute. ²Medical Research Unit-College of Medicine, Al-Nahrain University. ³Department of Obstetrics and Gynecology, College of Medicine. Al-Nahrain University, Baghdad, Iraq.

Abstract

Human papillomavirus (HPV) is the principle cause of cervical carcinoma (CC). Detection and screening programs for this malignancy is formerly based on cytological examination of cervical cells. However, the recent trend is for detection of HPV DNA in cervical swabs (CSs). In either cases, the collection of specimens require pelvic examination which is unfavorable for women and time consuming for healthcare providers. Using urine sample for HPV DNA detection is a very good alternative; however, the efficiency of such samples in this regard is questionable. This cross-sectional study aimed to evaluated the efficiency of urine samples in detection of HPV DNA compared with CSs, and to determine the genetic relatedness of local HPV isolates from urine and CSs through phylogenetic analysis. Pair samples of first voided urine and CSs were collected from a total of 100 married women with child bearing age suffering from vaginal discharge. Cervical swabs were kept at -20°C until be used, while urine samples were processed at the same day of collection. From both specimens, viral DNA was extracted and two sets of universal primers were used to amplify L1 capsid gene in a nested-PCR, the products of which were subjected for direct sequencing. The resultant sequences were aligned with reference sequences in Gen Bank. MEGA 6 software was used to construct the phylogenetic tree from local isolates and 19 reference sequences. HPV DNA was detected in 13% and 10% of CSs and urine samples respectively. Phylogenetic analysis for local HPV isolates from cervical samples revealed that 8 (61.54%) isolates were low risk (LR) HPV. The other five isolates were high risk (HR) HPV. Kappa statistic revealed 0.853 concordance between urine samples and CSs in HPV DNA detection (95% confidence interval (CI)=0.0.696–1.01, P<0.001), with 96.7% sensitivity and 100% specificity. These data strongly indicated the efficiency of urine sample in HPV detection with excellent sensitivity and specificity. Thus, urine samples could be used for routine detection and screening for HPV infection in women with child-bearing age.

Keywords: Human Papilloma Virus, Urine samples, malignancy, Iraqi women, vaginal discharge.

*Correspondence: sciencefond2015@gmail.com

(Received: 15 September 2018; accepted: 09 November 2018)

Citation: Ali D. Marhash, Qasim S. Al-Mayah, Enas A.A. Al-Kazaaly, Detection and Phylogenetic Analysis of Human Papilloma Virus in Urine from a Sample of Iraqi Women with Vaginal Discharge, *J Pure Appl Microbiol.*, 2018; **12(4)**:2183-2192. http://dx.doi. org/10.22207/JPAM.12.4.57

© The Author(s) 2018. **Open Access**. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Journal of Pure and Applied Microbiology

INTRODUCTION

Human papillomavirus is a group of more than 200 related viruses which can be distinguished by their genetic variability¹. Globally, this virus is one of the most common cause of sexually transmitted diseases (STDs) in both men and women². According to their association with cancers, HPV types were categorized in to low risk (LR) HPV and high risk (HR) HPV. High risk HPV is thought to be the principle cause of human cervical cancer⁴, a considerable proportion of other anogenital cancers⁵, and oropharyngeal cancers⁶.

Cervical cancer (CC) is the fourth most common cancer worldwide, with an estimated 528000 new cases and 26600 deaths⁹. Of note, the majority of cases are squamous cell carcinoma and adenocarcinoma. About 85% of these cases occur in low and middle-income developing countries¹⁰. In Iraq, cervical cancer is less common than other developing countries and ranked tenth among women age 15 to 45-year-old, with about 300 annual cases¹¹.

Studies showed that early detection HPV in urogenital specimens through screening programs could significantly decrease the occurrence of CC. It was estimated that a woman needs only several screens in her lifetime to achieve this task¹². A remarkable decline both in the CC-related morbidity and mortality was reported during the last decades in many high-income countries as a result of screening programs⁴. World Health Organization (WHO) has recommended such programs in a (screen and treat) manner strategy for women with child-bearing age¹³.

Screening programs were initially based on Papanicolaou (Pap) and direct molecular detection of HPV from different urogenital specimens¹⁴. In either cases, there will be a need for pelvic examination. Such procedure has many disadvantages especially in conservative society like Iraqi. It is invasive and uncomfortable for the women and cannot be carried out in settings with poor resources. Moreover, it is time consuming for healthcare provider¹⁵. Therefore, it is not feasible for screening test, at least, among Iraqi population.

A proper alternative is using urine sample for HPV DNA detection. Using this alternative has many advantages, among which are urine sampling is preferred and acceptable by all women, it is non-invasive and can be self-collected, there is no need for pelvic examination, and finally many other sexually transmitted infections can be detected simultaneously¹⁶. However, there are many drawbacks in this procedure: urine is diluted and contain polymerase chain reaction (PCR) inhibitors like urea and nitrites and HPV DNA can be deteriorated by contaminating bacteria and/or endonuclease¹⁷.

MATERIALS AND METHODS

A cross-sectional study including 100 child-bearing age women suffering from vaginal discharge was conducted. Those women were attending the department of Gynecology at Al-Imamain Al- Kadhumain Medical City/Baghdad from December 2017 to April 2018. Inclusion criteria include married women within childbearing age suffering from vaginal discharge. Exclusion criteria include treated cases of cervical cancer, pregnant women and women with hysterectomy. Data were taken from each women including age, age at sexual initiation, total life time sex partner, number of wives for a husband,

Table	1.	Total	number	of	women	and
demog	rap	hic dist	ribution.			

Variable	No (%)
Age (years)	
20-30	28 (28%)
31-40	38(38%)
41-50	34(34%)
Age at marriage (years)	
≥ 25	12 (12%)
< 25	88 (88%)
Duration of sexual activity	
\geq 10 years	75 (75%)
<10 years	25 (25%)
Number of wives of husband	
One	69 (69%)
Two	31 (31%)
Previous marriage	
Yes	8 (8%)
No	92 (92%)
Genital warts	
Absent	94 (94%)
Present	6 (6%)
Dwelling	
Rural	65 (65%)
Urbans	35(35%)

a previous marriage, and cervical examination for presence of warts in genital tract.

The present study was approved by the ethical committee of the College of Medicine/Al-Nahrain University.

Samples collection Urine

From each woman, 20-30 ml of first voided urine were collected in a sterile container, transported to the lab, and centrifuged at 14000 rpm for 20 minutes to give urine sediment. DNA was extracted immediately from sediments with a ready extraction kit.

Cervical Swabs

Special endocervical swab was taken from the patient by a gynecologist and put in ice back or stored in -20°C until be used.

Extraction of genomic DNA from urine and CS was done using a commercial ready kit (viral DNA extraction α (Genaid/Taiwan) according to the manufacturer's instructions.

Two sets of primers MY09/MY11 and GP5+/GP6+ primers, that amplify the L1 region of viral genome were used in a nested PCR. MY09/ MY11 primers amplify approximately 450 bp of the gene, while the pair of GP5+/GP6+ amplify 150 bp, which is internal to the sequence flanked by the former primers.

The second polymerase chain reaction products of L1 gene were directly sequenced (Macrogen /Korea). The obtained sequences were aligned with normal sequence from GenBank.

Data Analysis

Statistical package for social science (SPSS) was used for all statistical analyses. Variables were expressed as frequency and percentage and analyzed with Chi-square Phylogenic relevance between local isolates and reference isolates and within local isolates were calculated using MEGA 6 software with 1000 bootstrap replicates. A p-value of <0.05 was considered statistically significant.

RESULTS

Demographic Data of the study population

The present study enrolled 100 women suffering for vaginal discharge. Twelve percent from women were more than 25 years at marriage. Seventy five percent have sexual activity more than 10 years. About one third of women in current study have second-wife. Only 8% of women have a previous marriage. Warts represent approximately 6% of study cases. About two-third (65%) of studied women were from rural regions (Table 1). **Molecular Detection**

Gel electrophoresis of PCR product for L1 gene was shown in figures (1) and (2) respectively. **Sequence Alignment**

PCR products from the second round for both CSs and urine samples were subjected to direct sequencing. The resultant sequences were undergone BLAST in NCBI web page, according which 19 somewhat similar sequences were chosen for the alignment and for construction of phylogenetic tree with the isolates belonging to the current study. The accession numbers of reference sequences were AF548837.1, DQ448211.1 (type 18), AF548824.1, DQ448197.1, LC155223.1 (type 16), HG793863.1, KM01523.1 (type 6), FN70704.1




Fig. 1. Gel electrophoresis of nested- PCR products of Human Papillomavirus L1 capsid gene (the first round) stained with ethidium bromide and visualized under ultra-violate. M: DNA marker, Lanes 2 and 6: positive results for amplification (450bp). Lanes 1,3,4,5 and 7: negative results.




Fig. 2. Gel electrophoresis of nested-PCR products of Human Papillomavirus L1 capsid gene (the second round) stained with ethidium bromide and visualized under ultra-violate. M: DNA marker, Lanes 1,2,3,4,5 and 6: positive results for amplification (150bp). Out of 100 CSs, 13 (13%) were found to be positive for HPV DNA. On the other hand, HPV DNA was successfully isolated from 10 samples (10%) out of 100 urine samples collected from the same women.

Marhash et al. J Pure Appl Microbiol, 12(4), 2183-2192 | Dec. 2018 | http://dx.doi.org/10.22207/JPAM.12.4.57

	10 20 30 40 50 60 70 80 90 100
type 16 ype 16	TTTTGTTACTGTGGTAGATACTACACGCAGTACAAAATATGTCATTATGTGCTGCCATATCTACTTCAGAACCTACAATATAAAAATACTAACTTTAAAGAG
type 18	
vpe 18 vpe 6	GTG.TACTGT.GTAGATACTACTCGCAGTACC.AT.TAACAATATGTGCTT.TACA.AGTCCTGTA.CTGGGCA.T.TGATGCTCAA.TTT.A GT.ACTGTG.TAGATAC.ACACGCAGTACCATGACAT.ATGTGCA.C.GTA.CTACA.CTTCC.ACCA.TTCTG.TTAAAG.GTACA
e 6	GACAT.ATGCATCC.TATCTTCCT.C.CCAAT.CTGA.TA.AAAGAG.AC.TGCGTC.TGTGGA.G.AT.TGTTAC.GTTTTT
11	GT.ACTGTG.TAGATAC.ACACGCAGTACATATGACAC.ATGTGCA.CTGTGTCTACA.CTGGTACTA.TTC.G.TTAAGGTACA
45 51	GT.ACTGTA.TGGACACTAC.CGCAGTACTT.TAACAT.ATGTGCCTACACAAA.TCCTGTGC.AAGT.CTG.CCCTACTAAG.TT.AGC
58	. G. ACCGTG. T. ATACC CGTA C AT. TG. CA. T GCAC AA. TA. CTAAAGAAGATAC. TA A. A T TT GGAAT. T. TA
52 56	.G. AC.GTG. A.ATACCGTAC. AC.TG.CT.T.GTGC. AG.TG. TATGTGACAGC.CATATA.A.ATGATT.T.AGGA.T.CCT GT.ACTGTA.TAGATACTACT.GAAGTACTCATGACTGTACTGCTACAG.AC.GT.AATGATGC.CG.A.AATTAA.C.GTACC
∍ 56 ∋ 66	. GT. ACTGTG. TAGATACTAC GARGTAC CATGACT ATGCAGCGT. A. G. AC. A. T. ACTAATATG GC CGTGA T. AATC. ATA
35	GT. ACTGTG. TAGATACTAC. GTAGTACTAC TATGTCTG. GTGT. CTGCTGTGTCTACTAGTGAC. GTACATATA TG., A. TT A. GGA. T
33 39	GT. ACTGTG. TAGATACTACTCGCTTG. A. TCA. ACAA. GTAACTAG.G.CC. AG
59	TAACAGTTAGATACTACTCGCAGCACTCT.TCTG.GTGTGCT.CTACCT.CTCCT.TTC.TA.TGC.C.CCTACCAGTT.A.
68 16	CT. ACTGT. TGGATAC. ACTCGCAGTACT.T. ACTT. GTCTACTACTAC.GAA. CAGCTGT.C.AA.TT. TG. TCCTA.TAAA.TT.AG.
10	A .GACCTACATCC .GTGT .TAAATC .G. T. CATACA . TAAT. CCAGATTATA .GGA .TACATCG ATGTGGAGG TATGATTTACAGTTT .T
	CGGCTCACACT.TATGTGC.TC.TGT.ACT.C.CCTG.CCACATACACCTA.TC.AGAATAGGAGATACATGCGTCCA.GTGGAAGG.ATA
	.GGCTCCGACT.TATGTGC.TCT.ACTAC.TCC.TC.CACACA.CAATTCTGA.TA.AAGTAC.TGCG.C.TGTGGAAGTAA.ATG.TTT AAC.TCCTGAC.TA.GTGC.TCCGTAA.TAC.TCTTCCACAT.CACCAATTCTGATAA.GAGT.C.TG.GTG.GGGA.TATGACTT
	GGGCAAATGAC.TA.GTGC.TCCGTAA.TAC.TCTTCCACAT.CACCAATTCTGATAA.GAGT.C.TG.GTG.GGGA.TATGACTT
	AAAATAACTGACTTAT. TGCA. C. GTAACTACATCT. CCACATAC. CCAAT. CTG TATA. AGAGTAC. TGCGTCATGTGG G. A TGA T. CAGT AC. C. G. TAT. GC. C. GTA TACA CTTCCACATA CC AT CTCATT AAG. G A TGCGTC TG GG G TG TT AC CTTTA
	AC.CC.GTATGCC.GTATACA.CTTCCACATACC.AT.CTGATTAAG.G.ATGCGTC.TG.GGGTG.TT.AC.GTTTA CGGCTCACACT.TATGTGC.TC.TGT.ACT.CCCTG.CCACATACACCTATC.AGAATAGGRGATACATGCGTCCA.GTGGAAGG.ATA
	GTG.TAATGT.GTAGATACTACTCGCAGTACC.AT.TAACAATATGTGCTT.TACA.AGTCCTGTAGCTGGGCA.T.TGATGGTCAA.TTT.A
	G. GT. ACTGTG. TAGATACTAT. GAAGTACCATGACAATGCAGCGT.A.G.AC.A.T.ACTAAATATCGCCGTGAT.T.AATC.ATA ACAAAAA.AACTTG.G.AT.CGTA.CTC.TCCAACACCAA.T.TGAT.A. AAGAGT.CATGCGTCGTGG.AGAAT.TGA.TT.C
	ACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
	ACAATCACTGACTTAT.TGCA.C.GTAACTACATCT.CCACATAC.CCAAT.CTGTATA.AGAGTAC.TGCGTCATGTGG.G.A.TGA.TCAGT
	ACCACA.GACT.ATGT.CAT.CGT.ACT.CAT.TTCC.CA.ACACCAA.TATTATAAAGAG.ACATG.G.CATGTGGG.ATA.G.T.AC.GTT CAC.TAGCTGACTTAT.TGCA.C.GTAACTACATCC.TCCAACACCAA.T.TGAT.A.AAGAGT.CATGCGTCGTGG.AGAAT.TGA.TT.C.
	.CGCTCATACCTG.G.AT.CT.TGACTAC.TCCC.TACACA.CTAAT.C.GATTA.A.AGGAGATACATGCGTCCATG.GGAAGGTAT.
	G TG. TAATGT. GTAGATACTACTCGCAGTACC. AT. TAACAATATGTGCTT. TACA.AGTCCTGTAGCTGGGCA.T. TGATGGTCAA.TTT.A
	Ст.
	110 120 130 140
	TACCTACGACATGGGGAGGAATATGATTTACAGTTTA
16 18	TACCTACGACATGGGGAGGAATATGATTTACAGTTTA C. GTATA. CAGACAT. TT GG. AT GATTTACAGT
16 18 18	TACCTACGACATGGGGAGGAATATGATTTACAGTTTA C.GTATA.CAGACAT.TTGG.ATGATTTACAGT GCAGTAGGACATGTTG.GGAATA.G.TTTACAG
≥ 16 ≥ 18 ≥ 18 ≥ 6	TACCTACGACATGGGGAGGAATATGATTTACAGTTTA C. GTATA. CAGACAT. TT GG. AT GATTTACAGT
16 18 18 6 6 11	TACCTACGACATGGGGAGGAATATGATTTACAGTTTA C.GTATA.CAGACAT.TTGG.ATGATTTACAGT GCAGTAGGACATGTTG.GGAATA.G.TTTACAG .G.G.CATGTGGAA.AGTATGAT.T.CAATTTAT.C C G.GCCATGTGGA.AGTTTGAT.T.CAGTTTAT.CA
16 18 18 6 6 6 11 45	TACCTACGACATGGGGAGGAATATGATTTACAGTTTA C.GTATA.CAGACAT.TTGG.ATGATTTACAGT GCAGTAGGACATGTTG.GGAATA.G.TTTACAG .G.G.CATGTGGAA.AGTATGAT.T.CAATTTAT.C C .G.GCCATGTGGAAGTTTGAT.T.CAGTTTAT.CA AGTAGT.G.CAT.TG.AGGAATGA.TT.CAG.T.A.
e 16 e 18 e 18 e 6 e 6 e 11 e 45 e 51 e 58	TACCTACGACATGGGGAGGAATATGATTTACAGTTTA C.GTATA.CAGACAT.TTGG.ATGATTTACAGT GCAGTAGGACATGTTG.GGAATA.G.TTTACAG .G.G.CATGTGGAA.AGTATGAT.T.CAATTTAT.C C .G.GCCATGTGGA.AGTATGAT.T.CAGTTAT.CA AGTAGT.G.CAT.TC.AGGA.ATGA.TT.CAG.T.A. .TA.TA.S.G
e 16 e 18 e 18 e 6 e 6 e 11 e 45 e 51 e 58 e 52	TACCTACGACATGGGGAGGAATATGATTTACAGTTTA C. GTATA. CAGACAT. TT GG. AT GATTTACAGT GCAG TAG GACATGTTG. GGAATA. G. TTTACAGC .G. G. CATGTGGAA. AGTATGAT. T. CAATTTA T. C C. G. GCCATGTGGA AGTTTGAT. T. CAATTTA T. CA AGTA GT. G. CAT. TG. AGGA. ATGAT. T. CAG. T. A. TA. TA. G A. CGT. ATGATG. A. AATATG T. ACAG. TT CA CGT. T. G. GA TAATATG T. ACAG. TT TC
e 16 e 18 e 18 e 6 e 11 e 45 e 51 e 58 e 52 e 56 e 66	TACCTACGACATGGGGAGGAATATGATTTACAGTTTA C.GTATA.CAGACAT.TTGG.ATGATTTACAGT GCAGTAGGACATGTTG.GGAATA.G.TTTACAG .G.G.CATGTGGAA.AGTATGAT.T.CAATTTAT.C C .G.GCCATGTGGA.AGTATGAT.T.CAGTTAT.CA AGTAGT.G.CAT.TC.AGGA.ATGA.TT.CAG.T.A. .TA.TA.TA.G CGT.ATGTTG.A.AAT.TC.TAC.GTGTTCA .CGTC.T.G.GA.AATATGA.T.CAGTTTTC .TAGACATGTGGA.A.TATGA.T.CAATTTT CCTTCG.C.TGA.GAAT.GATTAT.CC
e 16 e 18 e 6 e 6 e 11 e 51 e 55 e 55 e 56 e 35	TACCTACGACATGGGGAGGAATATGATTTACAGTTA C. GTATA. CAGACAT.TTGG.ATGATTTACAGT GCAGTAGGACATGTTG.GGAATA.G.TTTACAG G.G.CATGTGGAA.AGTATGAT.T.CAATTTAT.C C.G.CATGTGGA.AGTATGAT.T.CAATTTAT.CA AGTAGT.G.CAT.TGA.AGA.ATGAG.TT.CAG.T.A.G.T.A. CGT.ATGTTG.A.AAT.TC.TAC.GTGTTCA CGT.ATGTTG.A.AATT.TCAATTAC.TTC CGTCG.C.TGA.GAATGATT.A.CGT.A.T ACTTA.GA.GAT.AGAT.AC.GT.AT ACTTA.G.CATG.T.A.A.TATGAT.AC.GT.AT
e 16 e 18 e 18 e 6 e 6 e 11 e 51 e 55 e 52 e 56 e 35 e 33	TACCTACGACATGGGGAGGAATATGATTTACAGTTTA C.GTATA.CAGACAT.TTGG.ATGATTTACAGT GCAGTAGGACATGTTG.GGAATA.G.TTTACAG .G.G.CATGTGGAA.AGTATGAT.T.CAATTTAT.C C .G.GCCATGTGGA.AGTATGAT.T.CAGTTAT.CA AGTAGT.G.CAT.TC.AGGA.ATGA.TT.CAG.T.A. .TA.TA.TA.G CGT.ATGTTG.A.AAT.TC.TAC.GTGTTCA .CGTC.T.G.GA.AATATGA.T.CAGTTTTC .TAGACATGTGGA.A.TATGA.T.CAATTTT CCTTCG.C.TGA.GAAT.GATTAT.CC
e 16 e 18 e 6 e 6 115 e 55 e 552 e 556 e 333 9 e 59	TACCTACGACATGGGGAGGAATATGATTTACAGTTA C. GTATA. CAGACAT.TTGG.ATGATTTACAGT GCAGTAGGACATGTTG.GGAATA.G.TTTACAGT G. G. CATGTGGAA.AGTATGAT.T.CAATTTAT.C C. G. GCCATGTGGAAGTTTGAT.T.CAGTTAT.CA AGTAGT.G.CAT.TG.AGGAATGA.TT.CAG.T.A. TA.TA.GA CGTC.TG.G.CAT.TG.AGGAT.CAG.TTATC CGTC.ATGTTGA.A.ATATGA.T.CAG.TT.TTC .TAGACATGTGGAA.TATGA.T.CAATTTT CCTTGG.C.TGA.GAATGATT.AC.GT.A.T ATTTA.GA.ATTGA.T.CAATTTT CCTGG.C.TGA.GAATGATT.AC.GT.A.T ATTA.ATT.A A.TA.GCTGTGAA.TATGA.TGA.TTCAAGTTA. A.TA.GG.ACGTG.AAT.TGTTACAGTTA. A.TA.G.C.G.CAT.TG.AGGATGA.TTGAAGTTA.
e 16 e 18 e 6 f 15 f 15 f 15 f 15 f 15 f 15 f 16 f 16 f 16 f 17 f 16 f 16 f 16 f 16 f 16 f 16 f 18 f 18 f 18 f 18 f 18 f 18 f 18 f 18	TACCTACGACATGGGGAGGAATATGATTTACAGTTA C. GTATA. CAGACAT.TTGG.ATGATTTACAGT GCAGTAGGACATGTTG.GGAATA.G.TTTACAGT G.G.CATGTGGAA.AGTATGAT.T.CAATTTAT.C AGTA.GT.G.CAT.TG.AGGA.TAGAT.T.CAGTTAT.CA AGTA.GT.G.CAT.TG.AGGA.TAGA.TT.CAG.T.AC CGT.ATGTG.A.AAT.T.C.TAC.GTGTTCA CGT.ATGTG.A.AAT.T.C.TAC.G.T.TC TAGACATGTGGA.A.TATGA.T.CAATTTT CCTTCG.C.TGAAT.ATATG.T.ACAGT.A.T. ATTA.G.CAGT.TG.AGAT.ATAGA.T.CAATTTT CCTTCGC.C.TGA.GAAT.GATT.A.CGT.A.T. ATTA.G.CATG.T.A.A.TATGAT.ACAGT.AT ATTA.A.CAGG.ACGTG.A.A.TATGAT.ACAGT.AT AC.AGG.ACGTG.A.A.TG.G.TTACAGTTTA.
e 16 e 18 e 6 e 6 11 51 52 66 55 52 66 53 33 99 e 68	TACCTACGACATGGGGAGGAATATGATTACAGTTA C. GTATA. CAGACAT.TTGG.ATGATTTACAGT GCAGTAG GACATGTTG.GGAATA.G. TTTACAGT G. G. CATGTGGAA.AGTATGAT.T. CAATTTAT.C C. G. GCCATGTGGAAGTTTGAT.T. CAGTTAT.CA AGTAGT.G.CAT.TG.AGGAT.AGA.TT.CAG.T.A. TA.TA.GA CTG. ATGTTG.A.AATT.TC.TAC.GTGTTCA CGTC.ATGGTGAAATATGA.T.CAG.TT.A.T CGT.CATGTGGAA.ATATGA.T.CAG.TT.A.T ATTTA.G.CATG.T.A.CAGT.A.CAGT.A.T TA.ATT.A.A.TATGA.T.CAATTTT CCTTCG.C.TGA.GAATGATT.AC.GTT.A.T ATTTA.G.CATGT.A.A.TAGA.T.GATTAACAGT.A. TA.ATT.A.A.TTACAGTTA. A.TA.C.GC.CATG.T.A.GAGA.ATGA.TTGCAA.T.A.A A.TATT.GGCAT.TT.AGGAATGA.TTGCAA.T.A.A TATT.GCATATT.AGGAATGA.TTGCAA.T.A.A A.TAT.GCATTAT.AGGA.ATGA.TTGCAA.T.A.A
e 16 e 18 e 6 e 6 11 51 52 66 55 52 66 53 33 99 e 68	TACCTACGACATGGGGAGGAATATGATTTACAGTTA C. GTATA. CAGACAT TT GG. AT GATTTACAGT GC.G. TAG GACATGTTG. GGAATA. G. TTTACAGT G. G. CATGTGGAA. AGTATGAT. T. CAATTTA T. C AGTAGT. G. CAT. TG. AGGA. ATGATT. CAGTTA T. CA AGTAGT. G. CAT. TG. AGGA. ATGA. TT .CAG. T. A.
e 16 e 18 e 6 e 6 e 11 e 51 e 55 e 556 e 556 e 333 9 e 68 e 68 e 69 e 333 e 59 e 68	TACCTACGACATGGGGAGGAATATGATTTACAGTTA C. GTATA. CAGACAT.TTGG.ATGATTTACAGT GCAGTAG GACATGTTG.GGAATA.G.TTTACAGT G. G. CATGTGGAA.AGTATGAT.T.CAATTTAT.C C. G. GCCATGTGGAAGTTTGAT.T.CAGTTAT.CA AGTAGT.G.CAT.TG.AGGAT.AGA.TT.CAG.TA. TA.TA.GA CGT.ATGTTG.A.AATT.TCTAC.G.TGTTCA CGT.C.TG.G.CATATGGA.T.CAGTTAT.C CGT.C.TG.G.A.ATATGA.T.CAG.TT.TT CCTCG.C.TGA.GAATGATT.AC.GT.A.T ATTTA.G.CATGT.A.A.TAGAT.ACAGTTA.A.T. TA.ATT.A.A.TAGAT.ACAGTTA.A.T. ATTA.ATT.A.A.TAGAT.ACAGTTA.AT ATA.ATT.A.GCATG.AGGA.ATGA.TTGCAG.T.A.A A.TA.C.CGCAT.TT.AGGA.ATGA.TTGCAA.T.A.A A.TAT.GGCAT.TT.AGGA.ATGA.TTGCAAG.CAT
e 16 e 18 e 6 e 6 e 11 e 51 e 55 e 556 e 556 e 333 9 e 68 e 68 e 69 e 333 e 59 e 68	TACCTACGACATGGGGAGGAATATGATTTACAGTTTA C. GTATA. CAGACAT TT GG AT GATTTACAGT GCAG TAG GACATGTTG GGAATA .G TTTACAG G. G. CATGTGGAA .AGTATGAT .T .CAATTTA T. C C G. G. CCATGTGGA AGTTTGAT .T .CAATTTA T. CA AGTA GT CAGA AGTAT.GA .TT .CAG .TA CGT AGT G. CAT .TG AGGA TAGA .T CGT ATGTG .A. AAT.TG T. CAGGTTCA CGT T. G. G. AT. TG T. CAGGT .T CA CCTTCG C. T. G. GA.T A.TATGA T. CAAGTTTC
e 16 e 18 e 6 e 6 e 11 e 51 e 55 e 556 e 556 e 333 9 e 68 e 68 e 69 e 333 e 59 e 68	TACCTACGACATGGGGAGGAATATGATTTACAGTTA C. GTATA. CAGACAT.TTGG.AT. GATTTACAGT GCAG. TAG. GACATGTTG.GGAATA.G.TTTACAGT G. G. CATGTGGAA.AGTATGAT.T.CAATTTAT.C C G. GCCATGTGGAAGTTTGAT.T.CAGTTAT.CA ACTA. GT. G.CAT.TG.AGGA.ATGA.TT.CAG.T.A.
e 16 e 18 e 6 f 15 f 15 f 15 f 15 f 15 f 15 f 16 f 16 f 16 f 17 f 16 f 16 f 16 f 16 f 16 f 16 f 18 f 18 f 18 f 18 f 18 f 18 f 18 f 18	TACCTACGACATGGGGAGGAATATGATTTACAGTTA C. GTATA. CAGACAT TT GG.AT. GATTTACAGT GC.G. TAG., GACATGTTG. GGAATA. G. TTTACAGT G. G. CATGTGGAA. AGTATGAT.T. CAATTTAT.C C. G. CATGTGGA. AGTATGAT.T. CAATTTAT.CA AGTA GT. G. CAT. TG. AGGA. AGTATGAT.T. CAGTTAT.CA AGTA GT. G. CAT. TG. AGGA. ATGAT.T. CAGTTAT.CA CGT. ATGTTG. A. AAT.TGT. ACAG. TT. A.CA CGT. ATGTTG. A. AATATGT. ACAG. TTTC TAGACATCTGGAA ATATGAT. CAATTTT CCTTCG.C. TGGAAT. GAAT. AC.GT. A.T ATTTA.G. CATG. T.A. A. TATGAT. A.CAGTAT ATTTA.G. CATG.T.A. A. TATGAT. A.CAGTAT ATTA.G. CATG.T.A. A. TATGAT. A.CAGTAT ATTA.G. CATG.T.A. A. TATGAT. A.CAGTAT ATTA.A. TT. A. A. TA. G. C.G. CAT. TG. AGGAATGA.TTGCAGTTA. A. TA. G.C.G. C.T. TA.GGA. ATGA. TTGCAGTTA. A. TA. G.C.G. CAT. TG. AGGA. ATGA. TGCCAGAAG. CAT
16 18 18 18 19 18 19 11 10 11 10 11 10 11 10 11 11 11 11 11 11 11 11 11 11 11 11 11 12 12 13 14 14 15 16 16 17 18 19 10 10 11 11 12 13 14 15 16 16 17 18 18 19 10 10	TACCTACGACATGGGGAGGAATATGATTTACAGTTA C. GTATA. CAGACAT.TTGG.ATGATTTACAGT GCAGTAGGACATGTGGA.AGTATGAT.T.CATTACAG G. G. CATGTGGAA.AGTATGAT.T.CAATTAT.C C. G. GCCATGTGGAAGTTTGAT.T.CAGTTAT.CA AGTAGT.G.CAT.TG.AGGAATGA.TT.CAG.TTCA AGTAGT.G.CAT.TG.AGGAATGA.TT.CAG.TTCA CGTC.ATGTTG.A.AAT.TCTAC.GTGTTCA CGTC.TG.G.A.GATATGG.T.ACAG.TTT CCTTCG.C.TGGAAATATGAT.CAATTAT CCTTCG.C.TGGAAATATGT.ACAG.TTT CCTTCG.C.TGGAAATATGT.ACAG.TT.A.CA ATTA.G.CATG.TA.A.ATATGAT.AC.GTT.AT ATTA.G.CATG.T.A.A.TATGAT.ACAGTTA. AC.AGG.ACGTG.AAT.TGTTACAGTTA. A.TA.G.C.G.CATG.TA.AATAGAT.ACAGT.A.A A.TA.G.C.G.CATT.TA.AGGATTGA.TTGCAG.T.A.A A.TA.G.C.G.CAT.TT.AGGAATGA.TTGCAATA.A A.TATT.GCATTAC.TAGCATTACATTA.CTGCAGAAG.CAT GAT.TAC.GT.TATTCT.TACA ACAG.T.T.TTCCAA.CCCAT .TT.TTCCAA.CCCAT .TT.TTCCAA.CCCAT .TT.TTCCAA.CCCAT .TT.TTCCAA.C .TAT.T.C.TACGT.TATTTCT.TACA
16 18 18 18 19 18 19 11 10 11 10 11 10 11 10 11 11 11 11 11 11 11 11 11 11 11 11 11 12 12 13 14 14 15 16 16 17 18 19 10 10 11 11 12 13 14 15 16 16 17 18 18 19 10 10	TACCTACGACATGGGGAGGAATATGATTTACAGTTA C. GTATA. CAGACAT TT GG.AT. GATTTACAGT GCAG. TAG., GACATGTTG. GGAATA. G. TTTACAGT G. G. CATGTGGAA. AGTATGAT.T. CAATTTAT.C C. G. CATGTGGA. AGTATGAT.T. CAATTTAT.CA AGTA GT. G. CAT. TG. AGGA. ATGAT.T. CAATTTAT.CA AGTA GT. G. CAT. TG. AGGA. ATGAT.T. CAGTTAT.CA CGT. ATGTTG. A. AAT.TG T. CAGTTCA CGT. ATGTTG. A. AATATGT. ACAG. TTTC TAGACATCTGGAA ATATGAT. CAAGTT.TT CCTTCG.C. TGGAAT. GAAT. AC.GT.T. A.T. ATTTA.G. CATG.T.A. CAATTTT CCTTCG.C. TGA GAAT. GAGT. AC.GT. A.T ATTTA.G. CATG.T.A. A. TATGAT. A.CAGTAT ATTA.G. CATG.T.A. A. TATGAT. A.CAGTAT ATTA.A. TT. A. A. TAA TT. A. A. TAA. G.C.G. C.T. TG. AGGAATGCATTA. A. TAA. G.C.G. CAT. TG. AGGAATGA.TTGCAG.T.A. A A. TAA TT. GGCAT.TT. AGGAATGA.TAGCATA.A. A. TAA CT. TGC. TAGCATTAACATTA. CTGCAGAAG. CAT
me 16 me 18 me 6 me 6 me 51 me 52 me 56 me 52 me 333 me 59 me 66	TACCTACGACATGGGGAGGAATATGATTTACAGTTTA C. GTATA. CAGACAT TT GG.ATGATTTACAGT GC.GTAGGACATGTTG. GGAATA. G. TTTACAGT G. G. CATGTGGAA. AGTATGAT. T. CAATTTA T. C AGTAGT.G. CAT.TG.AGGAATGA.TT.CAGTTAT.CA AGTAGT.G. CAT.TG.AGGAATGA.TT.CAG.T.A. .TA.TA.G. CGT.ATGG.A.AAT.A.C.TAC.GTGTTCA .CGTC.T.G.GAAATATGT.ACAG.TTTC .TAGACATGTGGAA. TATGA.T.CAATTTT .TTA.A.C.TGA.A.T.GAATGAT.T.A.T. ATTA.G.CATG.T.A.A.TATGA.T.CAATTTT .TTA.A.ATT.A.C.AATGAT.AC.GT.AT AC.AGG.ACGTG.AAT.TGTTACAGTTA. A.TA.G.C.G.CAT.TG.AGGATTGA.TTOCAGTTA. A.TA.G.C.G.CAT.TG.AGGATGA.TTOCAGTTA. A.TAC.TTGC.TAGCATTACATTA.CTGCAGAAG.CAT .GAT.TAC.GT.TATTCT.TACA ACAGG.T.T.TTCCA.A.GG .TT.TTC.A.CC .TATA.A. .TATA. .TATG.GAT.TATTCT.TACA ACAGG.T.T.TTCCA.C .TAT.TT.C.A.C.G. .TATTCCA.C .TAT.TTCCA.C .TAT.TTCCA.C .TAT.TTCA.A.G.G.TATTCT.TACA .G.AG.TAGGACATGATG.GAATA.G.TTTACAGT.
16 18 18 18 19 18 19 11 10 11 10 11 10 11 10 11 11 11 11 11 11 11 11 11 11 11 11 11 12 12 13 14 14 15 16 16 17 18 19 10 10 11 11 12 13 14 15 16 16 17 18 18 19 10 10	TACCTACGACATGGGGAGGAATATGATTTACAGTTA C. GTATA. CAGACAT TT GG AT GATTTACAGT GCAG TAG GACATGTTG GGAATAG. TTTACAG G. G. CATGTGGAA .AGTATGAT .T .CAGTTTA T. C AGTA GT CG AGTTGGAA AGTA CG
me 16 me 18 me 6 me 6 me 51 me 52 me 56 me 52 me 333 me 59 me 66	TACCTACGACATGGGGAGGAATATGATTTACAGTTTA C. GTATA. CAGACAT TT GG.ATGATTTACAGT GC.GTAGGACATGTTG. GGAATA. G. TTTACAGT G. G. CATGTGGAA. AGTATGAT. T. CAATTTA T. C AGTAGT.G. CAT.TG.AGGAATGA.TT.CAGTTAT.CA AGTAGT.G. CAT.TG.AGGAATGA.TT.CAG.T.A. .TA.TA.G. CGT.ATGG.A.AAT.A.C.TAC.GTGTTCA .CGTC.T.G.GAAATATGT.ACAG.TTTC .TAGACATGTGGAA. TATGA.T.CAATTTT .TTA.A.C.TGA.A.T.GAATGAT.T.A.T. ATTA.G.CATG.T.A.A.TATGA.T.CAATTTT .TTA.A.ATT.A.C.AATGAT.AC.GT.AT AC.AGG.ACGTG.AAT.TGTTACAGTTA. A.TA.G.C.G.CAT.TG.AGGATTGA.TTOCAGTTA. A.TA.G.C.G.CAT.TG.AGGATGA.TTOCAGTTA. A.TAC.TTGC.TAGCATTACATTA.CTGCAGAAG.CAT .GAT.TAC.GT.TATTCT.TACA ACAGG.T.T.TTCCA.A.GG .TT.TTC.A.CC .TATA.A. .TATA. .TATG.GAT.TATTCT.TACA ACAGG.T.T.TTCCA.C .TAT.TT.C.A.C.G. .TATTCCA.C .TAT.TTCCA.C .TAT.TTCCA.C .TAT.TTCA.A.G.G.TATTCT.TACA .G.AG.TAGGACATGATG.GAATA.G.TTTACAGT.
pe 16 pp 18 pp 6 pp 6 pp 51 pp 56 pp 56 33 9 pp 68	TACCTACGACATGGGGAGGAATATGATTTACAGTTTA C. GTATA. CAGACAT.TTGG.ATGATTTACAGT G. G. GATGTGGGA.AGATGTG, GAATA.G. TTTACAGT G. G. COCATGTGGAA.AGTTGAT.CAGTTTAT.C C G. GCCATGTGGAA.AGTTGAT.T.CAGTTTAT.CA AGTA.GT.G.CAT.TG.AGGAATGA.TT.CAG.T.A. .TA.TA.TA.G
pe 16 pp 18 pp 6 pp 6 pp 51 pp 56 pp 56 33 9 pp 68	TACCTACGACATGGGGAGGAATATGATTTACAGTTA C. GTATA. CAGACAT TT GG.AT. GATTTACAGT GC.G. TAG., GACATGTTG. GGAATA. G. TTTACAG G. G. GCATGTGGA. AGTATGAT.T. CAGTTAT.C AGTA. GT.G.CAT.TGAAGA. ATGA.TT. CAGTTAT.CA AGTA. GT. G. CAT.TG.AGGA. ATGA.TT. CAG.T.A. TA. TA. G. C.T. C. AGGA. ATGA.TT. CAG.T.A. TC CGT. ATGG. A.ATTC. TAC.GTGTTCA CGT. T.G.GA AATATGT. CAGTT.TTC GAGCATGTGGA. A. TATGA.T. CAGTT.A.T. CCTTCG.C.TGA.GATGAT. AC.GT. A.T. TA. ATT. A. ATA. ATT. A. A.TATA A.TA
ppe 16 ppe 16 ppe 18 ppe 18 ppe 18 ppe 18 ppe 6 ppe 51 ppe 52 ppe 56 ppe 56 ppe 59 ppe 68 ppe 16	TACCTACCACATGGGGAGGAATAGATTACAGTTA C. GTATA. CAGACAT. TT GG. AT GATTTACAGT GC.AG TAG GACATGTTO . GGAATA. G. TTTACAG G. G. CATGTGGAA AGTATGAT. T. CAGATTA T. CC G J. G. G. CATGTGGAA AGTATGAT. T CAGATTA T. CC G. G. CATGTGGAA AGTATGAT. T. CAGATTA T. CA AGTA GT. G. CAT. TG. AGGA ATGA. TT CAGTTA T. CA CGT. ATGTTG. A AATT C. TAC. G TGTT CA
Tpe 16 Tpe 18 Tpe 6 Tpe 6 Tpe 51 Tpe 58 Tpe 56 Tpe 56 Tpe 56 Tpe 56 Tpe 53 Tpe 35 Tpe 33 Tpe 58 Tpe 33 Tpe 39 Tpe 68	TACCTACGACATGGGAGGAATAGATTACAGTTA C.GTATA. CAGACAT.TT GG AT GATTTACAGT GC.GTAG GACATGTT.G GAATTA T. C G. G. CATGTGGA AGTTTGAT. T. CAGTTA T. C J. G. G.CATGTGGA AGTTTGAT. T. CAGTTA T. C AGTA GT. G. CAT. TG, AGGA ATGA T. CAG.T. A
TPe 16 TPe 18 TPe 6 TPe 6 TPe 51 TPe 52 TPe 56 TPe 56 TPe 56 TPe 56 TPe 56 TPe 33 TPe 59 TPe 68	TACCTACCACATGGGGAGGAATAGATTACAGTTA C. GTATA. CAGACAT. TT GG. AT GATTTACAGT GC.AG TAG GACATGTTO . GGAATA. G. TTTACAG G. G. CATGTGGAA AGTATGAT. T. CAGATTA T. CC G J. G. G. CATGTGGAA AGTATGAT. T CAGATTA T. CC G. G. CATGTGGAA AGTATGAT. T. CAGATTA T. CA AGTA GT. G. CAT. TG. AGGA ATGA. TT CAGTTA T. CA CGT. ATGTTG. A AATT C. TAC. G TGTT CA

Fig. 3. Alignment of local isolates with reference sequences using BioEdit software. C:cervical swab, U: urine sample.

(type 11), LC155426.1(type 33), LC155238.1 (type 35), AF548857.1 (type 39), KC470250.1 (type 45), AF548859.1 (type 51), LC155228.1 (type 52), KT070115.1 (type 56), KJ467244.1 (type58), AB437934.1 (type 59), LC15524.1 (type 66), JQ902131.1 (type 68). Figure (3) shows the alignment results using BioEdit soft. It is obvious from the figure the high diversity between both the isolates and reference sequences and among the local isolates themselves. Pairwise alignment between isolates from CSs and that from urine samples using the same software (data not shown) revealed complete coincidence of all isolates from urine samples with the correspondent isolates from CSs from the same women. Thus the further genetic analysis will be restricted to the isolates from CSs.

According the phylogenetic tree depicted in figure (4) the local isolates clustered as

following: isolate number 1 clustered with accession number FN870704 type 11 (Slovenian isolate), isolate number 3 clustered with accession number HG793863 type 6 (Slovenian isolate), isolate number 4-7 clustered with accession number KM501523.1 type 6 (Thailand isolate), isolate number 9,10,12 clustered with accession number DQ448197.1 type 16 (Iranian isolate), isolate number 11 clustered with accession number AF548837.1 type 18 (Iranian isolate), isolate 13 clustered with LC1555254.1 type 66 (Kenyan isolate). On the other hand, both isolate 2 and 8 clustered with each other's and the closest reference isolate is HG793863 type 6 (Slovenian isolate).

Figure (4): Phylogenetic trees for L1 gene constructed by the neighbor joining method for 13 isolates from CSs and 19 reference isolates. Phylogenetic distances were measured by the




Fig. 4. Phylogenetic trees for L1 gene constructed by the neighbor joining method for 13 isolates from CSs and 19 reference isolates. Phylogenetic distances were measured by the Kimura two-parameter model and the trees were statistically supported by bootstrapping with 1000 replicates. Bootstrap values below 50% are not shown. Current strains are indicated with a red square.




Fig. 5. Distribution of high risk and low risk HPV types in different age groups

Kimura two-parameter model and the trees were statistically supported by bootstrapping with 1000 replicates. Bootstrap values below 50% are not shown. Current strains are indicated with a red square.

Association of High and Low Risk HPV Types with Different Age Groups

According to the International Agency for Research on Cancer evaluation, out of 13 detected isolates, 8 (61.54%) were LR HPV types, 4(30.77%) were HR HPV types and 1 isolate (7.7%) was possible carcinogenic. For statistical purposes, the latter isolated will be considered within HR HPV. The association of high and low risk HPV types with different age groups is depicted in figure (5). Both high and low risk types increases with age and were more prevalent among age group 41-50 years.

Concordance between Cervical Swab and Urine Samples in HPV DNA Detection

Agreement in the detection of HPV DNA between CSs and urine sample was calculated via kappa statistic which was 0.853(95% CI=0.0.696– 1.01, P<0.001), which is very good agreement. Using HPV detection in cervical samples as a reference for calculation of the accuracy of valid urine HPV results in sensitivity of 96.7% and specificity was 100%.

DISCUSSION

According to the result of CSs, the current study revealed 13% as an overall prevalence of HPV infection in Iraqi women with vaginal discharge. Several previous local studies were conducted to detect the prevalence and types of HPV in Iraq. Ali *et al.*¹⁹ investigated Kurdish women with different cervical lesions using a molecular method. They found 17.5% of these women were positive for different types of HPV. Fadhil *et al.*²⁰ recruited 188 women with cervical dysplasia (CIN I, II, III) and used Genoarray technique for viral detection. HPV DNA was detected in 28.94% in those women, the majority of whom had HR types. What seems high proportion in these two studies compared with the current study is somewhat illusive. That is because these studies dealt with women with cervical abnormalities. Although these abnormalities are not necessarily carcinoma, they are not doubt early stage of transformation, and there is a high probability for HPV to be involved. Therefore, the reported rates may be underestimated may be due to the limited capacity of the used technique.

In contrast, the current study enrolled women with normal cervical appearance, yet relatively high rate of HPV infection was reported. This can be explained by accuracy of detection assay. The nested –PCR with two sets of universal primers can detect the vast majority of HPV, and it is considered as a gold standard for HPV detection and typing²¹.

There is almost a global agreement about the decisive role of screening test in the protection against invasive CC. So far, the reliable screening for HPV depend on Pap test which detects abnormal cellular change or premalignant lesions in the cervical tissue. With advent of molecular methods, there is a trend towards a direct detection of HPV from CSs. In fact, these screening methods had dramatically reduced the incidence and mortality rate of cervical cancer²³.

There is almost a global agreement about the decisive role of screening test in the protection against invasive CC. So far, the reliable screening for HPV depend on Pap test which detects abnormal cellular change or premalignant lesions in the cervical tissue. With advent of molecular methods, there is a trend towards a direct detection of HPV from CSs. In fact, these screening methods had dramatically reduced the incidence and mortality rate of cervical cancer¹⁹.

Among the many drawbacks of CSs (either for Pap smear or molecular diagnosis) are the physical and psychological discomfort of women concerning pelvic examination. Moreover, the procedure is a time consuming for health care provider, and cervical cytology is susceptible for technical and subjective interpretation errors which may result in false negative results²⁰. The best alternative choice for HPV is urine sample. It is a non –invasive, less expensive and more acceptable method²¹. If the efficiency of such alternative is proven, the screening coverage could be increased considerably primarily by reaching population in resource-limited settings²².

One of the most interesting result in current study is the very high concordance between CS and urine samples in detection of HPV DNA (κ=0.853, 95% CI=0.696-1.01). To the best of our knowledge, this the first study in Iraq which used pair cervical and urine samples for HPV detection. Most result of international studies in this regard obtained encouraging findings although with some contrary. In a Spanish study including 125 women attending primary care unit for regular check –ups, Bernal *et al.*²³ compared the efficiency of urine samples with that of CSs in HPV DNA detection using Cobas test. The overall concordance rate was 0.76%, 95%CI=0.66-0.87, with 90.5% sensitivity and 95% specificity. Almost similar results were reported by Tani et al.24 in 107 Italian women with abnormal cytology, and by Bissett et al.²⁵ in 246 English women under-going routine colposcopy.

Moreover, some studies detect more genotypes in urine samples than CSs. In a recent study conducted in Thailand, Khunamornpong *et* $al.^{22}$ used paired urine and CSs during follow –up of 168 women with previous infection with HPV. Beside the excellent concordance rate between the two samples (\hat{e} =0.96, 95% CI =0.9-1), the authors found that the absolute number of genotypes detect in urine samples was higher than that of CSs.

However, it seems that the difference between these specimens are mainly attributed to the presence of LR HPV in urine samples but not in CSs. In a Canadian study including 200 women referred to colposcopy clinic due to abnormalities in cervical cytology, vulvar, vaginal and urine samples were self-collected for HPV detection. For, HR HPV the detection rate in these samples were 86.2%, 62.1% and 44.8% respectively, while these rates were 53.5%, 62.7% and 69.7% respectively for LR HPV. The authors explained the high rate of LR HPV detected in urine samples by the susceptibility of urethral epithelial tissue but not the cervix for some LR HPV²⁶. In contrast some studies indicated a low detective ability of urine samples compared to CSs. In a large population-based study including 5318 women who provided with self-collected urine, cervical and vaginal samples in UK, Stanczuk *et al.*²⁷ showed that urine samples had a slightly lower detection rate (11.6%) compared to CSs (14.7%) and vaginal swabs (16.6%).

These variations in the result between different studies are expected. That is because a large number of factors may interfere with the results. May be the most important of these factors are urine sampling and processing.

Regarding sampling, timing, and quantity of collecting are hypothetically very important. In the current study, the first voided urine with an average of 30 ml urine sample were used. There is a higher degree of variation between the different studies on which urine fraction is preferable for HPV DNA detection. As the aim is to analyze a maximum of exfoliate cells²⁸, it is reasonable to use the first voiding urine as it carries the largest number of these cells compared with the other fractions.

Regarding collecting time, some studies claimed that the first urination of the day has associated with better detection of HPV DNA than other collection times²⁹. Nevertheless, a more recent study found no significant difference in detection rate between urine samples collected at different times of day³⁰.

Concerning urine volume, some reports stated that a large volume of urine is preferred for better detection. Burroni *et al.* ³¹ used 60 ml of urine in a study that enrolled 216 twenty-five years women in Florence/Italy. Urine samples were positive for human DNA and the concordance between these sample and CSs exceeded 85%. This finding suggests a positive correlation between urine volume and exfoliated cells. However, such a large quantity of urine is not always available at one collection time.

Several other factors may affect the analytical sensitivity of HPV DNA detection in urine reviewed by Vosters *et al.*²⁸. These include storage conditions, quality of DNA extraction, amplification method, and the detection of amplified DNA. During the current study, urine samples were not stored. Rather, the DNA was extracted at the same day with an average of about 2-3 hours interval

Journal of Pure and Applied Microbiology

between collection and extraction. For the other factors, the processing was performed according to the available facilities and there was a check-up after every step to ensure a fluent progress.

As a rule of thumb values of Kappa from 0.40 to 0.59 are considered moderate, 0.60 to 0.79 substantial, and 0.80 outstanding. Most statisticians prefer for Kappa values to be at least 0.6 and most often higher than 0.7 before claiming a good level of agreement. The current study reported κ = 0.853,95% (Cl=0.0.696–1.01), with a sensitivity of 96.7% and a specificity of 100%. Almost similar result was obtained in many studies worldwide^{12,24,25}. It implies that most HPV DNA in CSs could be detected in urine samples, while all HPV DNAs detected in urine are already have detected in CSs.

Based on the results of phylogenetic analysis for HPV DNA isolated from cervical swabs and urine samples, there were 13 isolates, 8 of which are low risk (clustered with type 6 and type 11), while other 5 isolates were HR (clustered with type 16, 18 and type 66). Thus, 38.5% of the isolates may be considered oncogenic while 61.5% are non –oncogenic types. These current results do not agree with previous local studies^{16,17} in that most isolates in these studies were HR HPV.

Globally, the current results are in consistence with that obtained by papilloma Aziz et al.32 who reported high prevalence of LR HPV among Pakistani women with normal cervical cytology. The most prevalence genotypes in this study were type 6 (25%) followed by type 55 (22.9%) and type 11(20.8%). In the African study, on the other hand, the HR HPV genotypes were predominant with type 16, 52, 18, and 51 were the most prevalence.33 In a recent large prospective study including 1218 Iranian women with normal cervical cytology, Hamkar *et al.*³⁴ found that HPV 16,18 and 66 were the most prevalent genotypes followed by type 11 and 6.

Interestingly, most LR HPV types reported in the current study are related Slovenian or Thailand isolates, while most HR HPV types were related to Iranian isolates. For high risk types, these results are very reasonable because of geographical reasons. However, for low risk types, it appears that Slovenian isolates have a global distribution because it was frequently reported in other geographical regions like Pakistan³².

CONCLUSION

According to the results of this study, it can be conclude that The incidence rate of HPV genital infection among Iraqi child-bearing women is comparable with that of neighboring Arabic and Islamic countries. Women with late stages of childbearing age and those with a second wife are more prone for HPV infection. Urine samples can be a very good alternative for vaginal swab for HPV DNA detection from suspected women or for routine detection. The study recommends routine use of HPV detection from urine samples especially for HR HPV such as type 16 and type 18 following the steps reported in this study. As the efficiency of urine sample is proved, wide screening programs should be adopted to determine the prevalence and types of HPV using molecular methods.

REFERENCES

- Bernard, H.U., Burk, R.D., Chen, Z., et al. Classification of papillomaviruses (PVs) based on 189 Types and proposal of taxonomic amendment. Virol. 2010;40(1):70-79.
- Le, H.H., Bi, X., Ishizaki, A., *et al*. Human papillomavirus in male patients with STI related symptoms in Hanoi, Vietnam. *J. Med. Virol*. 2016;**88**(6):1059-66.
- Denny, L., de Sanjose, S., Mutebi, M., *et al.* Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and highincome countries. *Lancet* 2016;**389**(10071):861-870.
- Heideman, D.A., Waterboer, T., Pawlita, M., et al. Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. J. Clin. Oncol. 2007; 25(29):4550–4556.
- Syrjanen, S., Lodi, G., von Bultzingslowen, I., et al. Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral Dis. 2011; 17 Suppl 1:58–72.
- International Agency for Research on Cancer: GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. <u>http://globocan.iarc.fr/Default.asp.</u>
- Bosch, F.X., Broker, T.R., Forman, D., et al. Comprehensive control of human papillomavirus infections and related diseases. *Vaccine* 2013;31 Suppl 7:H1-31.
- 8. Human papillomavirus and Related Diseases Report, 2017. Available at:http://www.hpvcentre. net/statistics/reports/XWX.pdf.
- 9. Schiffman, M., Castle, P.E. The promise of global cervical-cancer prevention. *New Engl. J. Med.* 2005;

353:2101–2104.

- World Health Organization. Guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Geneva, Switzerland: World Health Organization; 2013. Available at: <u>www. who.int/reproductivehealth/publications/caners/ screening_and_treatment_of_precancerous_ lesions/en.</u>
- Isidean, S.D., Coutlee, F., Franco, E.L. Cobas 4800 HPV Test, a real-time polymerase chain reaction assay for the detection of human papillomavirus in cervical specimens. *Expert Rev. Mol. Diag.* 2014;14: 5-16.
- Bernal, S., Palomares, J.C., Artura, A., *et al.* Comparison of urine and cervical samples for detecting of human papillomavirus (HPV) with the Cobas 4800 HPV test. *J. Clin. Virol.* 2014;**61**(4):548-552.
- 13. Vorsters, A., Micalessi, I., Bilcke, J., *et al.* Detection of human papilloma virus in urine. a review of the literature. *Eur. J. Clinic. Microbiol. Infect. Dis.* 2012;**31**:627-640.
- Howard, M., Sellors, J., Kaczorowski, J., et al. Optimal cutoff of the hybrid capture II human papillomavirus test for self-collected vaginal, vulvar, and urine specimens in a colposcopy referral population. J. Low Genit. Tract Dis. 2004;8(1):33– 37.
- Venceslau, E.M., Bezerra, M.M., Mota, A.C., et al. HPV detection using primers MY09/MY11 and GP5+/GP6+ in patient with cytologic and/or colposcopic changes. J. Bras. Patol. Med. Lab. 2014; 4(50):280-285.
- Ali, K.S., Jubrael, J.M.S., Ali, H.Y.M. AOS4 detection of human papillomavirus DNA in patients with different cervical lesions in Kurdistan region, Iraq. *Eur. J. Cancer* 2012;48: S4-S5.
- Fadhil, H.Y., Saleh, D.S., Al-Hamdani, F.G. Detection of human papillomavirus-21 genotypes in a sample of Iraqi women with cervical abnormalities and cancer. *Canad. J. Sci.* 2014;8(1);2671-2676.
- Lee, S.H., Vigliotti, J.S., Vigliotti, V.S., Jones, W. From human papillomavirus (HPV) detection to cervical cancer prevention in clinical practice. *Cancers* (*Basel*) 2014;6(4):2072-2099.
- Safaeian, M., Solomon, D. Cervical cancer prevention-cervical screening: science in evolution. *Obstet. Gynecol. Clin. North Am.* 2007;**34**(4):739-748.
- Jin, X.W., Sikon, A., Yen-Lieberman, B. cervical cancer screening: less testing, smarter testing. *Cleve. Clin. J. Med.* 2011; **78**:737-747.
- Petignat, P., Vassilakos, P. Is it time to introduce HPV self-sampling for primary cervical cancer screening. *J. Natl. Cancer Inst.* 2012;**104**(3):166-167.

- 22. Khunamornpong, S., Settakorn, J., Sukpan, K., *et al.* Comparison of human papillomavirus detection in urine and cervical samples using high-risk HPV DNA testing in North Thailand. *Obstet. Gynecol. Int.* 2016; **2016**:6801491.
- Bernal, S., Palomares, J.C., Artura, A., et al. Comparison of urine and cervical samples for detecting of human papillomavirus (HPV) with the Cobas 4800 HPV test. J. Clin. Virol. 2014;61(4):548-552.
- Tanzi, E., Bianchi, S., Fasolo, M.M., *et al.* High performance of a new PCR-based urine assay for HPV-DNA detection and genotyping. *J. Med. Virol.* 2013;**85**(1):91-98.
- Bissett, S.L., Howell-Jones, R., Swift, C., *et al.* Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males. *J. Med. Virol.* 2011;83(10):1744-1751.
- 26. Sellors JW, Lorincz AT, Mathony JB, et al. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect highgrade squamous intraepithelial lesions. CMAJ 2000;163(5):513-518.
- Stanczuk, G., Bater, G., Currie, H., et al. Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the papillomavirus Dumfries and Galloway-PaVDaG study). BMJ Open 2016;6(4):e010660.
- Vorsters A, Micalessi I, Bilcke J, Leven M, ogers J, van Damme P. Detection of human papillomavirus in urine: a review of the literature. *Eur J Clin Microbiol Infect* 2012;**31**:627-640.
- Pathak N., Dodds J., Zamora J., Khan K. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. Br Med J 2014;349 doi: 10.1136/ bmj.g5264.g5264.
- 30. Senkomago V, Des Marais AC, Rahangdale L, Vibat CRT, Erlander MG, Smith JS. Comparison of urine specimen collection times and testing fractions for the detection of high-risk human papillomavirus and high-grade cervical precancer. J Clin Virol 2016;74:26–31.
- Burroni E, Bonani P, Sani C, et al. Human papillomavirus prevalence in paired urine and cervical samples in women invited for cervical cancer screening. J Med Virol 2015;87(3):508-515.
- Aziz, H., Iqbal, H., Mahmood, H. *et al.* Human papillomavirus (HPV) infection in females with normal cervical cytology: genotyping and phylogenetic analysis among women in Punjab, Pakistan. *Int. J. Infect. Dis.* 2018;66:83-89.
- 33. Ogemebo, R.K., Gona, P.N., Seymour, A.J., et al.

Prevalence of human papillomavirus genotypes among African women with normal cervical cytology and neoplasia: a systematic review and meta-analysis. *PLoS ONE* 2015;**10**(4): e0122488.

34. Hamkar, R., Shoja, Z., Ghavami, N., et al. Type-

specific human papillomavirus prevalence in Iranian women with normal cervical cytology: the impact of current HPV vaccines. *Intervirol* 2017;**60**(4):125-130.